The prevalence of bacterial overgrowth syndrome and its associated factors in patients with inflammatory bowel diseases (according to the data of the Novosibirsk registry)


Cite item

Full Text

Abstract

Aim. To assess the prevalence of bacterial overgrowth syndrome (BOS) and its risk factors in patients with inflammatory bowel diseases (IBD). Subjects and methods. The patients from the Novosibirsk IBD registry, who had undergone a hydrogen breath test (HBT) using a Gastro+ device, were examined. Results. In 93 IBD patients who had undergone a HBD, the prevalence of BOS was 48% (46.2% for ulcerative colitis and 51.2% for Crohn’s disease). There was a strong correlation between abdominal bloating, abdominal rumbling, and positive HBT results in both patient groups. During the HBT, the patients with BOS frequently complained of diarrhea, borborygmi, belching, and anxiety. Conclusion. The findings suggest that BOS is highly prevalent among patients with IBD. BOS is associated with clinical symptoms, such as abdominal bloating, abdominal rumbling, tearfulness, and irritability.

About the authors

Yu A Kulygina

Новосибирский государственный медицинский университет Минздрава России

Новосибирск, Россия

M F Osipenko

Новосибирский государственный медицинский университет Минздрава России

Новосибирск, Россия

M I Skalinskaya

Новосибирский государственный медицинский университет Минздрава России

Новосибирск, Россия

K D Palchunova

Новосибирский государственный медицинский университет Минздрава России

Новосибирск, Россия

References

  1. Bouhnik Y, Alain S, Attar A, Flourié B, Raskine L, Sanson-Le Pors MJ et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999;94(5):1327-1331. doi: 10.1111/j.1572-0241.1999.01016
  2. Осипенко М.Ф., Скалинская М.И., Кулыгина Ю.А., Холин С.И., Краснер Я.А. Что мы знаем о синдроме избыточного бактериального роста. Медицинский Совет. 2016;(9):70-74. doi: 10.21518/2079-701X-2016-9-70-74
  3. Парфенов А.И., Ручкина И.Н., Осипов Г.А., Калоев Ю.К. Дисбактериоз кишечника: вопросы биологической терапии. Трудный пациент. 2007;5:32-34.
  4. Scarpellini E, Giorgio V, Gabrielli M, Lauritano EC, Pantanella A, Fundarò C et al Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. 2009;155:416-420. doi:org/10.1016/j.jpeds.2009.03.033
  5. Sabaté JM, Jouët P, Harnois F, Mechler C, Msika S, Grossin M, Coffin B High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008;18:371-377. doi: 10.1007/s11695-007-9398-2
  6. Vanderhoof JA, Young RJ. Etiology and pathogenesis of bacterial overgrowth. Clinical manifestations and diagnosis of bacterial overgrowth. Treatment of bacterial overgrowth. UpToDate online, vol 18.1; Wellesley, 2010. Available from: http://www.uptodate.com. doi: 10.1007/978-1-60761-183-7_11
  7. Scarpellini E, Gabrielli M, Za T, Lauritano EC, Santoliquido A, Rossi E, Ojetti V, Cammarota G De Stefano V, Gasbarrini A. The interaction between small intestinal bacterial overgrowth and warfarin treatment. Am J Gastroenterol. 2009;104:2364-2365. doi: 10.1038/ajg.2009.288
  8. Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: Friend of foe? World J Gastroenterol. 2011;17(5): 557-566. doi:org/10.3748/wjg.v17.i5.557
  9. Michielan A, D’Incà R. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. Mediators Inflamm. 2015;2015:628157. doi:org/10.1155/2015/628157
  10. Antoni L, Nuding S, Wehkamp J, Stange E Intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1165-1179. doi: 10.3748/WJG.v20.i5.1165
  11. Lee S. Intestinal Permeability Regulation by Tight Junction: Implication on Inflammatory Bowel Diseases. Intest Res. 2015; 13(1):11-18. doi:org/10.5217/ir.2015.13.1.11
  12. Andrei M, Gologan S, Stoicescu A, Ionescu M, Nicolaie T, Diculescu M Small Intestinal Bacterial Overgrowth Syndrome Prevalence in Romanian Patients with Inflammatory Bowel Disease. Current Health Sciences Journal. 2016;42(2);151-156. doi:org/10.1093/ecco-jcc/jjv215
  13. Rubio-Tapia A, Barton SH, Rosenblatt JE, Murray JA. Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. J Clin Gastroenterol. 2009;43:157-161. doi:org/10.1097/mcg.0b013e/3191557e67
  14. Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther. 2009;29:1273-1281. doi: 10.1111/j.1365-036.2009.03994
  15. Runyon BA. Pathogenesis of spontaneous bacterial peritonitis. UpToDate on line, 18.1. Wellesley. 2010;1517-1541. doi:org/10.1016/b978-1-4160-6189-2.00091-3
  16. Ebert EC. The thyroid and the gut. J Clin Gastroenterol. 2010;44:402-406. doi:org/10.1097/mcg.0b013e3181d6bc3e
  17. Scarpellini E, Giorgio V, Gabrielli M, Lauritano EC, Pantanella A, Fundarò C et al Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. 2009;155:416-420. doi:org/10.1016/j.jpeds.2009.03.033
  18. Swidsinski A, Loening-Baucke V Spatial organization of intestinal microbiota in health and disease. UpToDate on line, 18.1. Wellesley, 2010;214-254. doi:org/10.1002/9781118409855.ch9
  19. Фадеева Н.А., Ручкина И.Н., Парфенов А.И., Щербаков П.Л.. Избыточный рост микрофлоры тонкой кишки как причина лактазной недостаточности. Тер. архив. 2015;87(2): 20-23. doi: 10.17116/terarkh201587220-23
  20. Парфенов А.И. Энтерология: Руководство для врачей. 2-е изд. М.: МИА, 2009:108-110.
  21. Klaus J, Spaniol U, Adler G, Mason RA, Reinshagen M, Tirpitz C. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn’s Disease. BMC Gastroenterol. 2009;9:61. doi:org/10.1186/1471-230x-9-61
  22. Sánchez-Montes C, Ortiz V, Bastida G, Rodríguez E, Yago M, Beltrán B et al. Small intestinal bacterial overgrowth in inactive Crohn’s disease: influence of thiopurine and biological treatment. World J Gastroenterol. 2014;20(38):13999-4003. doi:org/10.3748/wjg.v20.i38.13999

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies